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Abstract: The consumption of probiotic products is continually increasing, supported by growing
scientific evidence of their efficacy. Considering that probiotics may primarily affect health (either
positively or negatively) through gut microbiota modulation, the first aspect that should be
evaluated is their impact on the intestinal microbial ecosystem. In this study, we longitudinally
analyzed the bacterial taxonomic composition and organic acid levels in four fecal samples collected
over the course of four weeks from 19 healthy adults who ingested one capsule a day for
two weeks of a formulation containing at least 70 billion colony-forming units, consisting of
25% lactobacilli and 75% Bifidobacterium animalis subsp. lactis. We found that 16S rRNA
gene profiling showed that probiotic intake only induced an increase in a single operational
taxonomic unit ascribed to B. animalis, plausibly corresponding to the ingested bifidobacterial strain.
Furthermore, liquid chromatography/mass spectrometry revealed a significant increase in the lactate
and acetate/butyrate ratio and a trend toward a decrease in succinate following probiotic administration.
The presented results indicate that the investigated probiotic formulation did not alter the intestinal
bacterial ecosystem of healthy adults and suggest its potential ability to promote colonization resistance
in the gut through a transient increase in fecal bifidobacteria, lactic acid, and the acetate/butyrate ratio.
Keywords: DESeq2; ALDEx2; short-chain fatty acids; succinate; acetate; butyrate; lactate; fecal
microbiota; intervention trial
1. Introduction
The consumption of products containing probiotics, i.e., “live microorganisms that,
when administered in adequate amounts, confer a health benefit on the host” [1], is constantly
increasing worldwide, supported by the growing scientific evidence of their efficacy [2]. According to
the scientific literature and existing regulatory approaches, a positive effect can be obtained when
probiotics are ingested in a quantity of at least 1 billion microorganisms per day (Italian Ministry
of Health) or per serving (Health Canada) [1]. Nonetheless, several studies have suggested that
some beneficial effects can only be obtained by consuming much higher doses of probiotic cells [3–5].
In this context, a human intervention trial with two doses (7 and 70 billion) of a multispecies probiotic
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formulation revealed that the higher dose allowed an early and prolonged recovery, thus indicating a
potential greater permanence of probiotic cells in the gastrointestinal tract [6].
Consistent with the observation that higher doses can be more effective than lower doses and
due to improved industrial technologies for microbial biomass production and preservation, in recent
years, the market has seen the steady growth of probiotic formulations with an increased number of
viable microbial cells, reaching up to hundreds of billions of colony-forming units (CFUs) per single
dose. However, the ingestion of such amounts of microbial cells is not unprecedented. For example,
approximately one hundred billion live bacteria can be ingested by consuming 100 g of yogurt or other
traditional fermented products (kimchi, sauerkraut, etc.). Nonetheless, the abovementioned examples
refer exclusively to the ingestion with food of lactic acid bacteria, whereas probiotic formulations
often contain bifidobacteria, common inhabitants of the mammalian gut, which have been extensively
documented to provide numerous different health benefits to the human host [7]. In particular,
the bifidobacteria most commonly included in commercial probiotic formulations worldwide belong
to Bifidobacterium animalis subsp. lactis, a taxon constituted by closely related and isogenic strains [8],
whose probiotic properties have been investigated in several hundred scientific studies; these studies
have shown that these bacteria possess the ability to decrease intestinal transit time [9] and improve
constipation [10–12], prevent antibiotic-associated diarrhea [13,14], enhance innate immunity markers
in older people [15], improve outcomes related to gastrointestinal discomfort in healthy adults [16],
and alleviate atopic eczema symptoms in infants [17].
Bifidobacteria are not naturally present in food, except in small numbers and rare cases of
exceptions. One example of a food product containing bifidobacteria in its natural microbiota is kumis
(or airag), a Central Asian product made by fermenting raw unpasteurized mare’s milk that contains
approximately 6 million CFUs of bifidobacterial cells per ml [18]. Therefore, unlike several types of
lactic acid bacteria, viable bifidobacteria are not traditionally consumed in food, especially not in the
amounts consumed through the ingestion of modern probiotic formulations. It therefore appears
necessary to assess whether the intake of bifidobacteria can be considered safe even in higher quantities.
Particularly, considering that probiotics may perform part of their activity on the host by modulating the
gut microbiota, a first aspect that should be evaluated is the possible impact on the intestinal microbial
ecosystem exerted by probiotics containing a high number of viable bifidobacterial cells (here, arbitrarily
considered to be higher than 5 × 1010). To this aim, in this study, we longitudinally analyzed the
taxonomic composition of the fecal microbiota and short-chain fatty acid levels in 19 healthy adults
who ingested one capsule a day for two weeks of a probiotic formulation containing 7 × 1010 CFUs,
25% of which were lactobacilli, and 75% of which were Bifidobacterium animalis subsp. lactis.
2. Materials and Methods
2.1. Microbiological Composition of the Probiotic Formulation
The probiotic product studied here consisted of methylcellulose capsules with a declared microbial
concentration of 7 × 1010 CFUs, available on market in Italy with the commercial name “FlorMidabìl™”.
The formulation was made of a blend of four bacterial strains: B. animalis subsp. lactis Bl-04 (nominal
concentration of 5.25 × 1010 CFU per capsule), L. acidophilus La-14 (1.4 × 1010 CFU per capsule),
L. plantarum SDZ-11 (2.8 × 109 CFU per capsule) and L. paracasei SDZ-22 (7 × 108 CFU per capsule).
In addition, the capsules contained the following excipients: hydroxypropyl methylcellulose (coating
agent), microcrystalline cellulose (bulking agent), magnesium salts of fatty acids and silicon dioxide
(anti-caking agents), and titanium dioxide (coloring agent).
2.2. Intervention and Study Scheme
The trial consisted of a single-blind microbiological pilot study. The inclusion and exclusion
criteria were described in a previous publication [6]. The study protocol was approved by the Research
Ethics Committee of the University of Milan (opinion no. 50/17, 18 December 2017). The trial consisted
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of a two-week intervention (one probiotic capsule per day) followed by two weeks of follow-up.
Participants consumed the capsule with natural water in the morning, at least 30 min before breakfast,
or in the evening, at least 2 h after the last meal. Four specimens were collected from each of the 19
healthy adults (mean age 29.1 ± 8.8 years) of both sexes (12 females) according to the protocol shown
in Figure 1.
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study. T3 corresponds to the fecal sample collected between days 3 and 5, depending on the subject
(day 3 for most of the volunteers).
2.3. Assessment of Bacterial Cell Viability in Probiotic Capsules
Total and viable cells in probiotic capsules were quantified by flow cytometry, as previously
described [6]. In brief, the powder in the probiotic capsule was dissolved in Mitsuoka buffer (pH 6.5),
homogenized in a sterile bag by using a stomacher (Colworth Stomacher 400, Seward, West Sussex, UK),
serially diluted in the same buffer, and stained with the non-permeant red-fluorescent dye propidium
iodide and the cell-permeant green fluorescent dye, SYTO™ 24 (15 min incubation at 37 ◦C in the
dark). After staining, samples were immediately analyzed with a C6 BD Accuri™ flow cytometer
(BD Biosciences, San Jose, CA, USA; threshold settings: FSC-H: 5000 and SSC-H 2000; total volume
collected, 50 µL). The absolute flow cytometry count was carried out using Fluoresbrite polychromatic
red 2.0 mm microspheres as a reference.
2.4. Fecal Microbiota Taxonomic Profiling
Total DNA was extracted from fecal samples as previously described [6,19]. In brief, we used
the DNeasy PowerLyzer PowerSoil DNA extraction kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions with the only difference of incubating samples at 65 ◦C for 10 min after the
addition of C1 solution. The cell disruption step was performed with a Precellys bead beater (3 cycles of
6800 rpm × 30 s; Advanced Biotech Italia s.r.l., Seveso, Italy). Finally, DNA was analyzed at the Institute
for Genome Sciences (University of Maryland, School of Medicine, Baltimore, MD, USA) through
16S rRNA gene profiling with Illumina HiSeq 2500 rapid run sequencing of the V3-V4 variable region.
Pairing, filtering, taxonomic assignment, and taxonomic diversity analyses of raw amplicon sequencing
data were carried out by means of the bioinformatic pipeline Quantitative Insights Into Microbial
Ecology (QIIME) version 1.9.0 [20] with the GreenGenes database (version 13_5). FASTQ data have
been deposited in the European Nucleotide Archive (ENA) of the European Bioinformatics Institute
under accession code PRJEB36929.
2.5. Quantification of Organic Acids in Fecal Samples
Organic acids were quantified in feces by ultra-high-pressure liquid chromatography coupled
with high-resolution/high-accuracy mass spectrometry (UPLC-HR-MS) as previously described [21,22].
In brief, 100 mg of feces was extracted with 2 mL of 0.001% formic acid. Then, UPLC-HR-MS analysis
was performed on an Acquity UPLC separation module (Waters, Milford, MA, USA) coupled with
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an Exactive Orbitrap MS through a HESI-II probe for electrospray ionization (Thermo Scientific,
San Jose, CA, USA). Finally, the UPLC eluate was analyzed by full scan MS in the 50–130 m/z range.
Five-point external calibration curves were prepared for the quantification of acetic, butyric, lactic,
propionic, succinic, and valeric acids.
2.6. Statistical Analysis
Statistical analysis of data was carried out using R statistic software (version 3.4.2). Data from
taxonomic diversity analysis were analyzed by the Wilcoxon-Mann-Whitney test. Significantly different
bacterial taxonomic units between time points were determined using differential gene expression
analysis based on the negative binomial distribution method (R/Bioconductor DESeq2 package; [23])
and the ANOVA-Like Differential Expression tool (R/Bioconductor ALDEx2 package; [24]) followed
by Welch’s t-test. In both analyses, p values were FDR-adjusted [23] (0.05 was used as the threshold
for significance). SCFA quantification data were analyzed by paired Student’s t-test with a p < 0.05
significance level, whereas 0.05 < p < 0.10 was considered to indicate a trend. Correlation analysis
between bacterial relative abundance and SCFA concentration was performed using Spearman’s ρ test.
3. Results
3.1. Content of Viable Microbial Cells in the Probiotic Formulation
Nineteen capsules of the probiotic product under study (one per volunteer) were randomly selected
and analyzed by flow cytometry to quantify the total and viable numbers of cells. Staining of bacterial
cells with SYTO™ 24 and propidium iodide revealed a total concentration of 5.08 (± 0.34) × 1011 cells
per capsule, with a viable count of 2.03 (±0.13) × 1011 cells per capsule, which corresponds to a viable
count 2.9-times greater than that indicated on the label (70 billion = 7 × 1010 CFUs per capsule).
This discrepancy between label specifications and the actual concentration of viable cells in the product
is expected, given that manufacturers of probiotic products apply an overdosage of live microorganisms
in the formulations to ensure that the number of surviving microbial cells is not lower than that
specified on the label until the end of the product’s shelf life.
3.2. Biodiversity of the Fecal Bacterial Community During the Probiotic Intervention
We used 16S rRNA gene profiling to characterize the bacterial taxonomic composition of 76 fecal
samples collected from 19 participants in the study. MiSeq sequencing generated 3,693,607 filtered
paired-end reads (mean of 62,603 reads per sample). The average quality per read (phred score) was 37.
The sequence length was between 301 and 596 bp, with an average of 460 bp. Overall, we identified
2525 unique operational taxonomic units (OTUs), with a mean and median number of 1019 and 967
per subject, respectively.
The analysis of α-diversity revealed that the probiotic intervention did not significantly affect the
taxonomic richness or evenness of the fecal microbiota structure (Figure 2A). To measure intersample
(β-)diversity, we examined the sequence reads with principal coordinate analysis based on weighted
and unweighted UniFrac distances. This analysis showed that the overall fecal bacterial community
structure was not significantly different among the four phases of the study (Figure 2B).
Overall, these results indicate that the intake of the probiotic formulation did not significantly
alter the fecal bacterial community structure of the healthy adults participating in the trial.
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(a)α-diversity analysis; the panel shows three indexes that differently describe the richness and evenness
of bacterial communities in fecal samples. (b) β-diversity analysis based on principal coordinate
analysis of unweighted (left) and weighted (right) UniFrac distances. Each point in the graph represents
a different fecal sample. Colors indicate the different phases of the study, according to the legend on
the right. Black lines connect samples from the same subject. The percentages indicate the proportions
of variance explained by the first and second ordination axes.
3.3. Effect of the Probiotic Intervention on the Abundance of Fecal Bacterial Taxa
Subsequently, microbiomic data were used to identify the bacterial taxonomic groups affected
by the probiotic treatment. To this aim, 16S rRNA gene profiling data were normalized by DESeq2
binomial distribution and then statistically analyzed with Welch’s t-test to compare different time
points; six comparisons were performed: T0 vs. T3, T0 vs. T14, T0 vs. T28, T3 vs. T14, T3 vs. T28,
and T14 vs. T28. In addition to OTUs, the main taxonomic levels (phylum, class, order, family and
genus) were considered in the analysis. The obtained results revealed that the probiotic intervention
significantly modified the relative abundance of 3 OTUs, one ascribed to the genus Lactobacillus,
another to the genus Bifidobacterium, and the third to an undefined taxon of the family Lachnospiraceae
(Figure 3A). In particular, OTU nr. 34342, taxonomically assigned to the species Bifidobacterium animalis
and plausibly corresponding to strain B. animalis subsp. lactis Bl-04 administered with the probiotic
formulation, resulted in a significant increase after approximately 3 and 14 days of probiotic intake
compared to the level at baseline and T28 (Figure 4). In addition, a few taxa significantly increased after
the follow-up period: the phylum Proteobacteria, the classes γ-Proteobacteria and Bacilli, the order
Lactobacillales, and the genera Prevotella and Haemophilus (T28) (Figure 3A).
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Figure 4. Relative abundance of OTU X4426298 over the course of the probiotic intervention trial (OTU
taxonomy: p_Actinobacteria; c_Actinobacteria; o_Bifidobacteriales; f_Bifidobacteriaceae; g_Bifidobacterium;
s_animalis). Statistics according to Wilcoxon matched-pairs signed rank test; **** p < 0.0001; *** p < 0.001.
DESeq2 normalization considers the value “0” for taxa that have not been found in a sample.
Nonetheless, since 16S rRNA profiling data generated by NGS are compositional data, the read
count should be associated with a probability, which cannot be 1 or 0. To overcome this potential
drawback of DESeq2 normalization applied to (meta) genomic/transcriptomic dat , an ALDEx2
multivariate probability distribution was proposed [25]. Ther fore, subsequently, we perform d
ALDEx2 normalization of seque cing read abundances followed by Welch t-statistics, obtaining a
significant modific tion over he trial only for the taxon mic lev ls associated with the B a imal s OTU
4426298 (Figure 3B).
Overall, these results indicate that the administration of the probiotic product had a limited effect
on the relative abundance of specific fecal bacterial taxa, essentially resulting in the increase in a single
OTU ascribed to the species Bifidobacterium animalis.
3.4. Impact of Probiotic Intervention on the Fecal Levels of Organic Acids
As expected, acetate, propionate, and butyrate were found to be the most abundant SCFAs in fecal
samples. Succinate, valerate, and lactate were also detected and quantified (Figure 5). The probiotic
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intervention did not significantly affect the fecal levels of SCFAs. Nonetheless, we observed a significant
increase in lactate levels at T3 and a trend toward decreased succinate at T14. In addition, we also
found a significant increase in the acetate/butyrate ratio at T3 compared to the levels at T14 and T28
(Figure 5).
Finally, Spearman’s rho test revealed that the relative abundance of OTU 4426298 at T3 correlated
positively with the acetate/butyrate ratio (Spearman’s ρ = 0.389; p = 0.0338). At T3, a trend for a
negative association between OTU 4426298 and succinate was also observed (Spearman’s ρ = −0.344;
p = 0.0629). Conversely, these associations were not found at T14.
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confir ation that the intake of bifidobacterial strains can also be safe at higher concentrations is,
therefore, warranted.
e i testinal icrobiota of healthy adults is characteristically resistant and resilient, i.e., capable of
maintaining or re-establishing its taxonomic structure and ecosystem, respectively, upon ress r
lse ert r ti s [ ]. et eless, t e t icr i t i r i e l ti s is i ere tl less
resilie t, l si l s c se e ce f t e r ressi e l ss f ta ic i ersit t t cc rre
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during the westernization of human societies [29], resulting in the contraction of the “threshold of no
return”, i.e., the latitude of taxonomic fluctuations that permits the return to the initial state of the
microbial community structure [28]. We can speculate that the intake of probiotic products with a high
concentration of live cells could have a greater impact on the taxonomic structure of low-resilience gut
microbial ecosystems, such as those of westernized healthy adults. However, this hypothesis has never
been experimentally tested.
In the context described above, the primary aim of this study was the characterization of the effect
of a probiotic blend containing a high number (i.e., more than 50 billion) of viable bifidobacterial cells
on the fecal microbial ecosystem of healthy adults. Specifically, we studied a probiotic formulation
with a nominal concentration of 70 billion bacterial CFUs per capsule, 25% of which was composed of
three Lactobacillus strains (L. acidophilus La-14, L. plantarum SDZ-11, and L. paracasei SDZ-22) and 75% of
which was composed of the strain Bifidobacterium animalis subsp. lactis Bl-04. The intervention in our
project consisted of the administration of one probiotic capsule per day on an empty stomach, resulting,
therefore, in the intake of at least 52.5 billion CFUs of bifidobacterial cells, which is much greater
than the quantity of bifidobacteria that can be consumed in conventional foods. Then, in this study,
we assessed the “microbiomic safety” of the product (i.e., the potential consequences of its consumption
on the intestinal microbial ecosystem) by analyzing the feces of healthy adult volunteers recruited in a
highly urbanized European area (Milan metropolitan area, Italy). Specifically, the impact of the intake
of the probiotic formulation on the intestinal microbial ecosystem was assessed by 16S rRNA gene
profiling and SCFA quantification in fecal samples collected over the course of 4 weeks from 19 healthy
adult volunteers who ingested one capsule per day for 2 weeks. Similar studies have been carried
out with the popular probiotic product VSL#3, a blend of several bacterial strains, which has a large
amount of scientific literature attesting to its clinical efficacy. VSL#3 has a nominal concentration of
450 billion CFUs per dose, 60% of which was composed of Streptococcus thermophilus and approximately
30% of which was composed of B. animalis subsp. lactis (i.e., at least 135 billion bifidobacterial CFUs
per dose) [30]. In the study by Michail and Kenche, 24 subjects with diarrhea-predominant IBS
consumed 2 doses per day of VSL#3 for 8 weeks (i.e., nominally, 900 billion viable bacterial cells
per day, at least 270 billion of which were represented by bifidobacteria). Although authors found
improvement in specific Gastrointestinal Symptom Rating Scale (GSRS) scores, the fecal microbiota
composition, assessed using phylogenetic microarray, was not significantly affected [31]. More recently,
the administration of VSL#3 to 14 healthy women (two capsules a day for 4 weeks, each capsule
containing at least 112.5 billion viable bacterial cells) led to a significant reduction in the relative number
of circulating T helper 17 lymphocytes; nonetheless, the abundance of fecal bacterial taxa (investigated
through 16S rRNA gene profiling) and α-diversity did not change following administration of the
probiotic [32]. These studies indicate that the intake of probiotic bacteria (including bifidobacteria) at
doses of hundreds of billions of organisms is safe and suggest that the mechanism of action of such
probiotic products is plausibly not directly linked to the microbiota.
Similarly, the results of our study indicate that the intake of a high number of viable bifidobacterial
cells did not drastically affect the bacterial taxonomic composition in the feces of healthy adult
volunteers. Nonetheless, we observed a significant transient increase in the bifidobacteria introduced
by the probiotic. The bifidobacterial strain in the probiotic product under study, named B. animalis
subsp. lactis Bl-04, has extensive literature attesting to its properties, particularly in terms of
immunomodulation [33–36]. The modulation of immune responses by microorganisms in the gut is
mainly exerted in the ileum, where most of the intestinal structures of the mucosa-associated lymphoid
tissue (MALT) are located [37]. We can speculate that the localized action of the probiotic at the ileum
level could justify the limited influence on the bacterial community structure observed in feces.
Immunomodulation is promoted by the direct contact of microorganisms with the intestinal
mucosa, which is reasonably favored when the concentration of a specific microorganism is increased.
It has been calculated that, after the ingestion of 10 billion cells of a probiotic, assuming a 10% survival
rate during gastrointestinal transit, the relative proportion of ingested bacteria can reach a level of
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0.01- to 1-fold that of the resident bacteria in the ileum, therefore transiently becoming a dominant
member of the microbiota at that specific site, having the opportunity to interact directly with the
host [38]. Therefore, the intake of a larger amount of a probiotic strain with immunomodulatory
properties, such as B. animalis subsp. lactis Bl-04, might plausibly boost the establishment of a dialogue
with the ileal mucosa of the host.
Bifidobacteria are anaerobic fermentative bacteria that catabolize carbon sources into acetate and
lactate at a 1.5:1 ratio. Accordingly, during the probiotic intervention, we found an increase in fecal
lactate levels and the acetate/butyrate ratio. Specifically, the observed changes in fecal organic acid
concentrations were mainly observed at T3, i.e., a few days after the beginning of the probiotic intake
period, but returned to the initial levels at the end of the probiotic treatment (T14). Notably, correlation
analyses showed a positive association between the fecal levels of the B. animalis OTU 4426298 and the
acetate/butyrate ratio ad T3 but not at T14. These results suggest that the perturbation induced by
the intake of the probiotic product exerts its effect mostly during the first days whereas, subsequently,
it could be efficiently coped with by the resilience mechanisms of the gut microbiota of the healthy
adults participating in the trial. Furthermore, upon probiotic intake, we also observed a trend toward
a decrease in the fecal levels of succinate, a microbial product resulting from intestinal fermentation of
dietary fiber. An increase in intestinal succinate concentrations has been associated with dysbiosis and
enhanced inflammatory processes in the gut [39]; therefore, interventions that can reduce this organic
acid in the intestine can plausibly benefit the host.
In conclusion, this study indicates that the administration of the bifidobacterial strain Bl-04 at a
high dose through the administration of the investigated multistrain probiotic formulation (which also
included three different species of lactobacilli) was well tolerated by the intestinal microbial ecosystem
of healthy adult volunteers. In addition, the observed transient increase in fecal bifidobacteria,
lactic acid, and the acetate/butyrate ratio may contribute to the implementation of mechanisms that
are widespread among probiotics, such as colonization resistance and the competitive exclusion
of pathogens.
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